Zobrazeno 1 - 10
of 270
pro vyhledávání: '"George E. Bigelow"'
Autor:
Esther S Oh, Kaj Blennow, George E Bigelow, Sharon K Inouye, Edward R Marcantonio, Karin J Neufeld, Paul B Rosenberg, Juan C Troncoso, Nae-Yuh Wang, Henrik Zetterberg, Frederick E Sieber, Constantine G Lyketsos
Publikováno v:
PLoS ONE, Vol 13, Iss 9, p e0204695 (2018)
BACKGROUND:There is strong association of Alzheimer's disease (AD) pathology with gait disorder and falls in older adults without dementia. The goal of the study was to examine the prevalence and severity of AD pathology in older adults without demen
Externí odkaz:
https://doaj.org/article/efffaacbc9934cb0a0576bfd04be3ae7
Autor:
Ruth E. Winecker, Elia Goffi, George E. Bigelow, Ryan Vandrey, John M. Mitchell, Ronald Flegel, Edward J. Cone, David J. Kuntz, Tory R. Spindle, Dennis J. Sholler
Publikováno v:
J Anal Toxicol
The market for products containing cannabidiol (CBD) is booming globally. However, the pharmacokinetics of CBD in different oral formulations and the impact of CBD use on urine drug testing outcomes for cannabis (e.g., 11-nor-9-carboxy-Δ9-tetrahydro
Autor:
Cecilia L Bergeria, Tory R Spindle, Edward J Cone, Dennis Sholler, Elia Goffi, John M Mitchell, Ruth E Winecker, George E Bigelow, Ronald Flegel, Ryan Vandrey
Publikováno v:
J Anal Toxicol
There is limited data on the comparative pharmacokinetics of cannabidiol (CBD) across oral and vaporized formulations. This within-subject, double-blind, double-dummy, placebo-controlled laboratory study analyzed the pharmacokinetic profile of CBD,
Autor:
D. Andrew Tompkins, Eric C. Strain, Robert R. Edwards, George E. Bigelow, Andrew S. Huhn, Michael T. Smith
Publikováno v:
Anesthesiology. 130:131-141
EDITOR’S PERSPECTIVE What We Already Know about This Topic The prevalence of patients prescribed buprenorphine for treatment of opioid use disorder is increasing Managing acute pain in buprenorphine-maintained individuals can be challenging What Th
Publikováno v:
Addictive Behaviors. 86:56-60
Background Opioid-related overdose has increased 137% in the past decade. Training nonmedical bystanders to administer naloxone (Narcan™) is a widely-researched intervention that has been associated with decreases in overdose rates in the communiti
Autor:
Ronald Flegel, George E. Bigelow, John M. Mitchell, Evan S. Herrmann, Ryan Vandrey, Tory R. Spindle, Edward J. Cone, Charles LoDico
Publikováno v:
J Anal Toxicol
Oral cannabis products (a.k.a. “edibles”) have increased in popularity in recent years. Most prior controlled pharmacokinetic evaluations of cannabis have focused on smoked cannabis and included males who were frequent cannabis users. In this stu
Autor:
Mary M. Sweeney, MS, PhD, Denis G. Antoine, MD, Leticia Nanda, MS, CRNP, Hélène Géniaux, PharmD, Michelle R. Lofwall, MD, George E. Bigelow, PhD, Annie Umbricht, MD
Publikováno v:
Journal of opioid management. 15(5)
Objective: This study describes changes in weight and cardiovascular risk factors over time among individuals enrolled in methadone maintenance treatment for opioid use disorder. Demographic and clinical predictors of weight gain were also evaluated.
Autor:
George E. Bigelow, Shrinidhi Subramaniam, D. Andrew Tompkins, August F. Holtyn, Brantley P. Jarvis, Emmanuel A. Oga, Kenneth Silverman
Publikováno v:
Addiction. 113:1188-1209
Aims To review systematically the published literature on extended-release naltrexone (XR-NTX, Vivitrol® ), marketed as a once-per-month injection product to treat opioid use disorder. We addressed the following questions: (1) how successful is indu
Autor:
George E. Bigelow, Michael Fingerhood, Shrinidhi Subramaniam, Annie Umbricht, Brantley P. Jarvis, Kenneth Silverman, August F. Holtyn, Meredith S. Berry
Publikováno v:
Journal of Substance Abuse Treatment. 85:38-44
Background and aim Extended-release naltrexone (XR-NTX) blocks the effects of opioids for 4weeks; however, starting treatment can be challenging because it requires 7 to 10days of abstinence from all opioids. In the present study we identified patien
Autor:
Brantley P. Jarvis, Annie Umbricht, George E. Bigelow, Michael Fingerhood, Lauren Long, Anthony DeFulio, August F. Holtyn, Kenneth Silverman
Publikováno v:
Journal of Substance Abuse Treatment. 85:56-60
Background and aim Extended-release naltrexone (XR-NTX) blocks the effects of opioids for 4weeks, yet many patients continue to use them. To learn more about why this occurs, we collected self-reports on subjective effects and drug use factors from p